Alembic Pharmaceuticals share news and announcements
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,941 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 21.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,20,84752.2% delivered
Alembic Pharmaceuticals routine notices
389 filed, newest first. Page 2 of 8.
Apr 2025
3 Apr · Routine
Mar 2025
Feb 2025
Jan 2025
Dec 2024
2 Dec · Routine
Nov 2024
15 Nov · Routine
14 Nov · Routine
8 Nov · Routine
4 Nov · Routine
Oct 2024
25 Oct · Routine
23 Oct · Routine
21 Oct · Routine
10 Oct · Routine
7 Oct · Routine
1 Oct · Routine
Sep 2024
20 Sep · Routine
19 Sep · Routine
18 Sep · Routine
18 Sep · Routine
16 Sep · Routine
12 Sep · Routine
2 Sep · Routine
Aug 2024
21 Aug · Routine
14 Aug · Routine
9 Aug · Routine
6 Aug · Routine
5 Aug · Routine
Jul 2024
31 Jul · Routine
30 Jul · Routine
26 Jul · Routine
25 Jul · Routine
12 Jul · Routine
10 Jul · Routine
4 Jul · Routine
Jun 2024
26 Jun · Routine
26 Jun · Routine
24 Jun · Routine
18 Jun · Routine
7 Jun · Routine
5 Jun · Routine
May 2024
28 May · Routine
27 May · Routine